

Resultados e Discussão das Aulas Práticas

Ana Paula

Andriéli Bacega

Camila Cáceres

Danilo Ramos

Eunice Mateus Pires

Gislaine Silva

Henrique Santos Moure

Iara Bastos

Larissa Dunkl Brujas

Letícia Gonçalves dos Santos

Letícia Serafim da Costa

Lucas Ian Ribeiro

Maria Aiza Fontes Andrade

Nathália Cristina Lopes

Rebeca Jacinto Bonfim

Profa. Dra. Kelly Ishida

Profa. Dra. Gabriela Mol Avelar Tamaki


Prof. Dr. Sandro Rogerio de Almeida

Dra. Cristina de Castro Spadari


Dr. Daniel Felipe Freitas de Jesus

Tatiana Alves dos Reis


Transformação




Grupo 1



Grupo 2




Grupo 5



Grupo 6




Grupo 7



Grupo 8

Confirmação por PCR



Teste de Sensibilidade aos Antifúngicos

	AMB (CI ₉₀)	FLC (CI ₅₀)	ANF (CI ₅₀)
WT (G1)	0,12	0,12	≤ 0,008
Δ (G1)	0,06	0,12	≤ 0,008
CP (G1)	0,06	0,25	-
WT (G2)	0,06	0,25	0,007
Δ (G2)	0,06	0,125	0,007
CP (G2)	0,06	1	-
WT (G3)	0,125	0,125	<0,008
Δ (G3)	0,03	<0,06	< 0,008
CP (G3)	0,125	1	-
WT (G4)			
Δ (G4)			
CP (G4)			

QC for EUCAST antifungal testing


Candida parapsilosis ATCC 22019^a
Version 7.0, valid from 2023-08-14

See EUCAST E.Def 7.4 for MIC methodology

Antimicrobial agent	MIC ^b (mg/L)	
	Target	Range
Amphotericin B	0.25-0.5	0.125-1.0
Anidulafungin	0.5	0.25-1.0
Caspofungin	NA ^c	NA ^c
Fluconazole	1	0.5-2
Flucytosine	0.25	0.125-0.5
Isavuconazole	0.016	0.008-0.03
Itraconazole	0.06	0.03-0.125
Micafungin	1	0.5-2
Posaconazole	0.03	0.016-0.06
Rezafungin ^{##}	0.25-0.5	0.125-1
Voriconazole	0.03	0.016-0.06


	AMB (CI ₉₀)	FLC (CI ₅₀)	ANF (CI ₅₀)
WT (G5)	0,007	0,06	<0,07
Δ (G5)	<0,03	<0,25	<0,03
CP (G5)	0,06	0,125	-
WT (G6)	0,007	0,125	0,03
Δ (G6)	0,007	0,06	0,03
CP (G6)	0,007	0,5	-
WT (G7)	0,125	0,06 / 0,125 (?)	< 0,008
Δ (G7)	0,03	0,06	< 0,008
CP (G7)	0,03	1	-
WT (G8)	0,03	0,125	0,015
Δ (G8)	0,03	0,125	0,015
CP (G8)	0,06	1	-

Curva de Crescimento



Grupo 1

Curva de Crescimento



Grupo 2


WT SDA

Δ efg1/efg1 SDA

WT RPMI

Δ efg1/efg1 RPMI

Curva de Crescimento



WT SDA

$\Delta efg1/efg1$ SDA

WT RPMI


$\Delta efg1/efg1$ RPMI

G3

O meio SDA é rico em glicose e peptona, o que resulta em crescimento rápido e robusto.

O RPMI é um meio definido mais pobre em nutrientes, o que resulta num crescimento lento, moderado com formação de filamentos. A levedura detecta as limitações nutricionais do meio através de receptores membranares que desencadeiam no se citoplasma a expressão de proteínas envolvidas com o metabolismo adaptativo em resposta ao estresse para ativação, por exemplo, de mecanismos para utilização de outras fontes de carbono ou a produção de hifas para invasão de novos ambientes que possam suprir tais carências.

Curva de Crescimento



WT SDA


Δ efg1/efg1 SDA

WT RPMI

Δ efg1/efg1 RPMI

Grupo 5

Curva de Crescimento



Grupo 6


WT SDB

Δ efg1/efg1 SDB

WT RPMI

Δ efg1/efg1 RPMI

Curva de Crescimento



Grupo 7


WT SDA

Δ efg1/efg1 SDA

WT RPMI

Δ efg1/efg1RPMI

Curva de Crescimento



Grupo 8


WT SDA

Δ efg1/efg1 SDA

WT RPMI

Δ efg1/efg1 RPMI


Filamentação - RPMI/SDB/Spider




WT - SDB



efg1Δ/efg1Δ - SDB




WT - RPMI



efg1Δ/efg1Δ - RPMI

Filamentação - RPMI/SDB/Spider

Spider – Grupo 2



C.albicans WT







C.albicans Δ efg1

Spider – Grupo 3




Spider – Grupo 6

Virulência em *Galleria mellonella*




Ensaio de Fagocitose




Ensaio de Fagocitose


Controle




1:1






2:1



3:1




Cepa 1




Cepa 2


Ensaio de Fagocitose



Apenas
macrófagos
Poços 1 e 2



Macrófagos + *Candida*
misteriosa 1
Poços 3 e 4



Macrófagos + *Candida*
misteriosa 2
Poços 5 e 6